Skip to main content

Table 5 Univariate and multivariate Cox regression analysis for GBM cohort (n = 453)

From: A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

 

Univariate

Multivariate

OS

PFS

OS

PFS

HR

95 % C.I.

p-value

HR

95 % C.I.

p-value

HR

95 % C.I.

p-value

HR

95 % C.I.

p-value

Cohort

Cohort 1

0.81

0.643–1.030

0.09

1.11

0.884–1.398

0.37

excluded by factor selection with step-wise method

excluded by factor selection with step-wise method

Cohort 2

Ref

Ref

Location

Cerebrum

0.91

0.504–1.624

0.74

0.81

0.489–1.357

0.43

excluded by factor selection with step-wise method

excluded by factor selection with step-wise method

Cerebrum with Frontal Involvement

0.93

0.511–1.705

0.82

0.78

0.458–1.317

0.35

 

Other

Ref

Ref

Age

 

1.015a

1.004–1.025

0.006

1.004a

0.995–1.013

0.38

1.01a

1.004–1.025

0.008

excluded by factor selection with step-wise method

Sex

M

Ref

Ref

excluded by factor selection with step-wise method

excluded by factor selection with step-wise method

 

F

0.72

0.570–0.918

0.008

0.78

0.621–0.975

0.03

KPS

 

0.992b

0.985–0.999

0.03

0.999b

0.992–1.006

0.74

0.99b

0.982–0.997

0.009

excluded by factor selection with step-wise method

Surgery

Biopsy

2.59

1.725–3.899

<0.0001

2.06

1.349–3.130

0.0008

3.15

2.082–4.769

<0.0001

2.22

1.454–3.380

0.0002

 

Removal

Ref

Ref

Ref

Ref

TERT

wild-type

0.73

0.568–0.925

0.01

0.73

0.581–0.922

0.008

Interacts with MGMT

<0.0001

0.65

0.513–0.821

0.0003

 

mutated

Ref

Ref

 

Ref

MGMT

Methylated

0.43

0.325–0.561

<0.0001

0.51

0.396–0.656

<0.0001

Interacts with TERT

<0.0001

0.48

0.368–0.613

<0.0001

 

Unmethylated

Ref

Ref

 

Ref

TERT-MGMT

TERT-MGMT interaction

  

0.006

excluded by factor selection with step-wise method

 

Wt/Met

0.32

  
 

Mut/Met

0.27

  
 

Wt/Un-met

0.54

  
 

Mut/Un-met

Ref

  
  1. Chemo Chemotherapy, C.I. Coefficient interval, CRT chemoradiotherapy, F Female, GBM glioblastoma, HR hazard ratio, KPS Karnofsky Performance status, M Male, Met MGMT methylated, Mut TERT mutated, OS overall survival, PFS progression free survival, Ref Reference, RT radiation therapy, Un-met MGMT unmethylated, Wt TERT wild-type
  2. aHR is for each one year increase
  3. bHR is for each 1 % increase